IT Versione italiana

press conferences » Atrial Fibrillation and Stroke: the latest treatments

Anti-stroke efficacy: Watchman LAA Closure Device vs Warfarin. Press Conference by Boston Scentific

From 03.09.2013 to 03.09.2013    ESC 2013, Amsterdam

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia affecting over 5.5 million people worldwide. The most serious consequence of AF is ischaemic stroke. It is estimated that up to 20% of all strokes are related to AF. the most common and effective treatment is the use of the blood thinning medication Warfarin. Despite its proven efficacy, Warfarin therapy is not well-tolerated or may be difficult to control in many patients. The WATCHMAN LAA Closure Technology is a device alternative to Warfarin therapy in patients with non-valvular atrial fibrillation. By closing off the Left Atrial Appendage, the WATCHMAN Technology is designed to reduce the risk of stroke, cardiovascular death and systemic embolisation, potentially eliminating the need for long term Warfarin therapy.


speakers' interviews

Cookies helps us to provide our services. Using these services , you agree to use of cookies on our part. OK